David Menahem

Feb 6, 2024 | cellandgene.com | Moshe Szyf |Ahmed Abouzeid |Carol Houts |David Menahem

As the patient’s immune cells are the starting materials, inherent biological variability leads to CAR-T manufacturing. Additional critical raw materials also have batch-to-batch variability, which means the entire production process is a constant balancing act of adjusting the manufacturing process to create standardized manufacturing. Join Cell & Gene Live for a discussion on practical ways to overcome the challenges associated with batch-to-batch variation.